Case report: Long-term outcome of a heart transplant recipient switched to everolimus after an acute myocardial infarction

Transplantation

Volumn 82, Issue 8 SUPPL., 2006, Pages

  Frigerio, Maria ^a   Cipriani, Manlio G ^a   Roubina, Elena ^a   Orrego, Pedro Silva ^a   Vitali, Ettore ^a  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

Cardiac allograft vasculopathy; Everolimus; Heart transplantation; Immunosuppression; Late complications; Proliferation signal inhibitors mTOR inhibitors

Indexed keywords

AZATHIOPRINE; EVEROLIMUS;

ACUTE HEART INFARCTION; ADULT; ARTICLE; CARDIAC ALLOGRAFT VASCULOPATHY; CASE REPORT; CLINICAL FEATURE; DRUG SUBSTITUTION; HEART GRAFT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; LEUKOPENIA; LONG TERM CARE; MALE; PNEUMONIA; PRIORITY JOURNAL; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 33750343813     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000243153.84531.90     Document Type: Article

References (17)

1. Taylor DO, Edwards LB, Boucek MM, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-second official adult heart transplant report - 2005. J Heart Lung Transplant 2005; 24: 945.
2. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac transplant recipients. N Engl J Med 2003; 349: 847.
3. Mancini D, Pinney S, Burkhoff D, et al. Use of rapamycin slows progression of cardiac transplant vasculopathy. Circulation 2003; 107: 48.
4. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773.
5. Costa RA, Lansky AJ, Mintz GS, et al. Angiographic results of the first human experience with everolimus-eluting stents for the treatment of coronary lesions (the FUTURE I trial). Am J Cardiol 2005; 95: 113.
6. Hognestad A, Endresen K, Wergeland R, et al. Inflammatory response and restenosis after percutaneous coronary intervention in heart transplant recipients and patients with native atherosclerosis. J Heart Lung Transplant 2005; 24: 1026.
7. Sergovia J, Alonso-Pulpon L, Ortiz P, et al. Rapastat: evaluation of the role of oral sirolimus in the treatment of established graft vessel disease. A prospective, randomized intravascular ultrasound study. J Heart Lung Transplant 2004; 23(Suppl 2): S51.
8. Ramzy D, Rao V, Brahm J, Miriuka S, Delgado D, Ross HJ. Cardiac allograft vasculopathy: a review. Can J Surg 2005; 48: 319.
9. Keogh A. Improving outcomes in heart transplantation: the potential of proliferation signal inhibitors. Transplant Proc 2005; 37(Suppl 4): 1.
10. Benza RL, Zoghbi GJ, Tallaj J, et al. Palliation of allograft vasculopathy with transluminal angioplasty. J Am Coll Cardiol 2004; 43: 1973.
11. Eisen H, Kobashigawa J, Starling RC, Valantine H, Mancini D. Improving outcomes in heart transplantation: the potential of proliferation signal inhibitors. Transplant Proc 2005; 37(Suppl 4S): 4-17.
12. Ruygrok PN, Webber B. Faddy S, Muller DW, Keogh A. Angiographic regression of cardiac allograft vasculopathy after introducing sirolimus immunosuppression. J Heart Lung Transplant 2003; 22: 1276.
13. Kovarik JM, Dantal J, Civati G, et al. Influence of delayed initiation of cyclosporine on everolimus pharmacokinetics in de novo renal transplant patients. Am J Transplant 2003; 3: 1576.
14. Certican®SPC, Certican® summary of product characteristics. 2003, Basel: Novartis Pharma AG.
15. Zuckermann A. Clinical experience with Certican® (everolimus) in maintenance heart transplant patients at the Medical University of Vienna. J Heart Lung Transplant 2005; 24(Suppl 4): 206-209.
16. Lehmkuhl H, Ross H, Eisen H, Valantine H. Everolimus (Certican®) in heart transplantation - optimizing renal function through minimizing cyclosporine exposure. Transplant Proc 2005; 37: 4145.
17. Bjornsson TD, Callaghan JT, Einolf HJ, et al. The conduct of in vitro and in vivo drug-drug interaction studies: a pharmaceutical research and manufacturers of America (PhRMA) perspective. Drug Metab Dispos 2003; 31: 815.